Cme (CME) EBITDA (2009 - 2026)

Cme (CME) has 18 years of EBITDA data on file, last reported at $1.3 billion in Q1 2026.

• EBITDA for Q1 2026 came in at $1.3 billion, up 17.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 8.36% YoY), and the FY2025 annual result was $4.2 billion, up 7.58% from the prior year.
• EBITDA advanced to $1.3 billion in Q1 2026 per CME's latest filing, from $1.0 billion in the prior quarter.
• Over five years, EBITDA peaked at $1.3 billion in Q1 2026 and troughed at $668.3 million in Q4 2022.
• A 5-year average of $959.6 million and a median of $947.1 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA increased 29.16% in 2023, then fell 5.07% in 2025.
• A 5-year view of EBITDA shows it stood at $668.3 million in 2022, then gained by 29.16% to $863.2 million in 2023, then climbed by 9.72% to $947.1 million in 2024, then grew by 7.65% to $1.0 billion in 2025, then soared by 31.12% to $1.3 billion in 2026.
• Business Quant data shows CME's EBITDA at $1.3 billion in Q1 2026, $1.0 billion in Q4 2025, and $999.0 million in Q3 2025.